Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89,600,000
-
Total 13F shares
-
74,728,462
-
Share change
-
+10,780,185
-
Total reported value
-
$1,041,701,866
-
Put/Call ratio
-
96%
-
Price per share
-
$13.94
-
Number of holders
-
153
-
Value change
-
+$151,177,198
-
Number of buys
-
102
-
Number of sells
-
43
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q4 2023
As of 31 Dec 2023,
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) was held by
153 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
74,728,462 shares.
The largest 10 holders included
Alphabet Inc., ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., FEDERATED HERMES, INC., STATE STREET CORP, FMR LLC, T. Rowe Price Investment Management, Inc., Casdin Capital, LLC, and Nikko Asset Management Americas, Inc..
This page lists
153
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.